Open AccessHormone therapy in menopausal women with fibroids: is it safe? (Literature review)
Author(s) -
Ya. Z. Zaydieva
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-14(389)-38-44
Subject(s) - medicine , hormone therapy , asymptomatic , uterine fibroids , progestogen , estrogen , hormone replacement therapy (female to male) , selective estrogen receptor modulator , raloxifene , breast cancer , tamoxifen , hormone , menopause , gynecology , cancer , testosterone (patch)
Hormone therapy is an effective treatment option for menopausal women, although prolonged use of hormone therapy is associated with a slightly increased risk of breast cancer, thromboembolism, and stroke. A literature search for studies evaluating the effects of hormone therapy in menopausal women with asymptomatic fibroids demonstrated variable effects of hormone therapy on the volume and size of the fibroids. Some studies have demonstrated an increase in size of pre-existing asymptomatic fibroids and formation of new fibroids with higher doses of progestogen in combination therapy. Selective estrogen receptor modulators having tissue-specific estrogen agonistic and antagonistic actions such as raloxifene have a favorable clinical profile and may be better alternatives in women with asymptomatic fibroids.